M Bassetti1, D R Giacobbe2, C Grecchi3, C Rebuffi4, V Zuccaro5, L Scudeller6. 1. Department of Health Sciences, University of Genoa, Genoa, Italy; Clinica Malattie Infettive, Ospedale Policlinico San Martino - IRCCS, L.go R. Benzi 10, 16132 Genoa, Italy. Electronic address: matteo.bassetti@unige.it. 2. Department of Health Sciences, University of Genoa, Genoa, Italy; Clinica Malattie Infettive, Ospedale Policlinico San Martino - IRCCS, L.go R. Benzi 10, 16132 Genoa, Italy. 3. Infectious Diseases Unit, IRCCS San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, University of Pavia, Italy. 4. Scientific Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 5. Infectious Diseases Unit, IRCCS San Matteo, Pavia, Italy. 6. Scientific Direction, Clinical Epidemiology and Biostatistics, IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano Foundation, Milan, Italy.
Abstract
OBJECTIVES: To summarize the available evidence on the diagnostic performance for invasive aspergillosis (IA) in non-hematological, non-solid organ transplantation critically ill patients of the following: (i) existing definitions of IA (developed either for classical immunocompromised populations or for non-immunocompromised critically ill patients); (ii) laboratory tests; (iii) radiology tests. METHODS: A systematic review was performed by evaluating studies assessing the diagnostic performance for IA of a definition/s and/or laboratory/radiology test/s vs. a reference standard (histology) or a reference definition. RESULTS: Sufficient data for evaluating the performance of existing definitions and laboratory tests for the diagnosis of IA in critically ill patients is available only for invasive pulmonary aspergillosis. Against histology/autopsy as reference, the AspICU definition showed a promising diagnostic performance but based on small samples and applicable only to patients with positive respiratory cultures. Studies on laboratory tests consistently indicated a better diagnostic performance of bronchoalveolar lavage fluid (BALF) galactomannan (GM) than serum GM, and a suboptimal specificity of BALF and serum (1,3)-β-D-glucan. CONCLUSIONS: Evidence stemming from this systematic review will guide the discussion for defining invasive aspergillosis within the FUNDICU project. The project aims to develop a standard set of definitions for invasive fungal diseases in critically ill, adult patients.
OBJECTIVES: To summarize the available evidence on the diagnostic performance for invasive aspergillosis (IA) in non-hematological, non-solid organ transplantation critically illpatients of the following: (i) existing definitions of IA (developed either for classical immunocompromised populations or for non-immunocompromised critically illpatients); (ii) laboratory tests; (iii) radiology tests. METHODS: A systematic review was performed by evaluating studies assessing the diagnostic performance for IA of a definition/s and/or laboratory/radiology test/s vs. a reference standard (histology) or a reference definition. RESULTS: Sufficient data for evaluating the performance of existing definitions and laboratory tests for the diagnosis of IA in critically illpatients is available only for invasive pulmonary aspergillosis. Against histology/autopsy as reference, the AspICU definition showed a promising diagnostic performance but based on small samples and applicable only to patients with positive respiratory cultures. Studies on laboratory tests consistently indicated a better diagnostic performance of bronchoalveolar lavage fluid (BALF) galactomannan (GM) than serum GM, and a suboptimal specificity of BALF and serum (1,3)-β-D-glucan. CONCLUSIONS: Evidence stemming from this systematic review will guide the discussion for defining invasive aspergillosis within the FUNDICU project. The project aims to develop a standard set of definitions for invasive fungal diseases in critically ill, adult patients.
Authors: A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl Journal: Stud Mycol Date: 2021-05-10 Impact factor: 16.097
Authors: Rashid Nadeem; Aju Rafeeq; Anas A Aga; Ayesha Siddiqua; Ekta Sharma; Doaa Anwer; Mohd Kafeel Khan; Mohamed Abdulla Mohammed Hussein; Yusra Omar Alshaikh SayedAhmed; Farooq Ahmad Dar Journal: Cureus Date: 2022-07-18
Authors: Amir Arastehfar; Agostinho Carvalho; Frank L van de Veerdonk; Jeffrey D Jenks; Philipp Koehler; Robert Krause; Oliver A Cornely; David S Perlin; Cornelia Lass-Flörl; Martin Hoenigl Journal: J Fungi (Basel) Date: 2020-06-24
Authors: Thaila F Dos Reis; Laure N A Ries; Gustavo H Goldman; Aílton Pereira da Costa Filho; Guilherme Thomaz Pereira Brancini; Patrícia Alves de Castro; Clara Valero; Jaire Alves Ferreira Filho; Lilian Pereira Silva; Marina Campos Rocha; Iran Malavazi; João Guilherme de Moraes Pontes; Taícia Fill; Roberto Nascimento Silva; Fausto Almeida; Jacob L Steenwyk; Antonis Rokas Journal: mBio Date: 2020-10-13 Impact factor: 7.867